GSK Files NDA For Oncology Anti-Nausea Drug

Casopitant, follow-on to Zofran, is part of GSK’s larger plan to grow its oncology portfolio in supportive care.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet